Peripheral Nerve Damage with Prostate Cancer Drug May Be Predicted by a Gene Mutation

Peripheral Nerve Damage with Prostate Cancer Drug May Be Predicted by a Gene Mutation
A specific genetic variant of the VAC14 gene may be involved in the development of peripheral neuropathy following taxane administration, a group of drugs commonly used for breast, ovary, lung, or prostate cancer treatment. The findings were described in the study “Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of VAC14 Polymorphism That Increases

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *